Vladimir Vorobyev

2.4k total citations
39 papers, 383 citations indexed

About

Vladimir Vorobyev is a scholar working on Hematology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Vladimir Vorobyev has authored 39 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 18 papers in Pathology and Forensic Medicine and 16 papers in Molecular Biology. Recurrent topics in Vladimir Vorobyev's work include Multiple Myeloma Research and Treatments (17 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Vladimir Vorobyev is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Vladimir Vorobyev collaborates with scholars based in Russia, United States and Italy. Vladimir Vorobyev's co-authors include Alexandre M. Erkine, Tamara Y. Erkina, Kazuhito Yamamoto, Jalaja Potluri, Monique Dail, Brenda Chyla, Nicola Fracchiolla, Jun Ho Jang, Ying Zhou and Hartmut Döhner and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Vladimir Vorobyev

34 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vladimir Vorobyev Russia	10	228	185	137	85	45	39	383
Jessica Haug United States	10	244 1.1×	303 1.6×	141 1.0×	57 0.7×	57 1.3×	23	423
Emma C. Fink United States	6	249 1.1×	491 2.7×	172 1.3×	45 0.5×	37 0.8×	8	614
Tadasu Tobita Japan	10	206 0.9×	213 1.2×	77 0.6×	66 0.8×	35 0.8×	12	381
Evžen Gregora Czechia	11	253 1.1×	218 1.2×	130 0.9×	43 0.5×	22 0.5×	29	301
Joan Bladé Spain	6	416 1.8×	316 1.7×	238 1.7×	100 1.2×	31 0.7×	12	490
Roberta Rostagno Italy	5	284 1.2×	121 0.7×	93 0.7×	227 2.7×	41 0.9×	6	464
Hussein Ghamlouch France	11	79 0.3×	154 0.8×	52 0.4×	112 1.3×	88 2.0×	27	341
Silvia Bungaro Italy	6	210 0.9×	91 0.5×	64 0.5×	122 1.4×	25 0.6×	13	338
Hardik Modi United States	10	351 1.5×	223 1.2×	82 0.6×	222 2.6×	26 0.6×	17	588
Swathi-Rao Narayanagari United States	4	200 0.9×	194 1.0×	58 0.4×	61 0.7×	25 0.6×	4	374

Countries citing papers authored by Vladimir Vorobyev

Since Specialization

Citations

This map shows the geographic impact of Vladimir Vorobyev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimir Vorobyev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimir Vorobyev more than expected).

Fields of papers citing papers by Vladimir Vorobyev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimir Vorobyev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimir Vorobyev. The network helps show where Vladimir Vorobyev may publish in the future.

Co-authorship network of co-authors of Vladimir Vorobyev

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimir Vorobyev. A scholar is included among the top collaborators of Vladimir Vorobyev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimir Vorobyev. Vladimir Vorobyev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vorobyev, Vladimir, et al.. (2025). Anti-CD38 Antibodies in Monotherapy for Patients with Relapsed/Refractory Multiple Myeloma: Real-World Clinical Practice and Results of Clinical Trials. Clinical oncohematology. 18(2). 145–152.

Façon, Thierry, Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).. Journal of Clinical Oncology. 42(16_suppl). 7500–7500. 3 indexed citations

Niemann, Carsten Utoft, Talha Munir, Carolyn Owen, et al.. (2024). First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis. Blood. 144(Supplement 1). 1871–1871. 5 indexed citations

Trudel, Suzanne, Meral Beksaç, Luděk Pour, et al.. (2024). Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(17_suppl). LBA105–LBA105. 2 indexed citations

Orlowski, Robert Z., Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study. Blood. 144(Supplement 1). 770–770. 3 indexed citations

Façon, Thierry, Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ). Clinical Lymphoma Myeloma & Leukemia. 24. S31–S31. 2 indexed citations

Schweizer, Michael T., Atish D. Choudhury, Vadim Doronin, et al.. (2022). 488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC). Annals of Oncology. 33. S763–S764. 4 indexed citations

DiNardo, Courtney D., Keith W. Pratz, Panayiotis Panayiotidis, et al.. (2022). AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia. 22. S214–S214. 1 indexed citations

Lonial, Sagar, Sebastian Grosicki, Marek Hus, et al.. (2022). Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.. Journal of Clinical Oncology. 40(16_suppl). 8019–8019. 17 indexed citations

10.

Vorobyev, Vladimir, et al.. (2021). Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience. Terapevticheskii arkhiv. 93(7). 785–792.

11.

Bringhen, Sara, Luděk Pour, Vladimir Vorobyev, et al.. (2021). Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leukemia Research. 104. 106576–106576. 20 indexed citations

12.

Nikitin, Eugene, Anastasia A. Ignatova, Vladimir Vorobyev, et al.. (2020). Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. Journal of Thrombosis and Haemostasis. 18(10). 2672–2684. 18 indexed citations

13.

Poddubnaya, I V, Vladimir Vorobyev, Kamil Kaplanov, et al.. (2020). Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic. SHILAP Revista de lepidopterología. 22(2). 52–55.

14.

Vorobyev, Vladimir, et al.. (2019). Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma. SHILAP Revista de lepidopterología. 91(7). 41–51. 2 indexed citations

15.

Volodicheva, Elena, et al.. (2016). Therapy for primary mediastinal large B-cell lymphoma in accordance with the R-DA-EPOCH-21 program: The first results. Terapevticheskii arkhiv. 88(7). 37–37. 4 indexed citations

16.

Vorobyev, Vladimir, et al.. (2016). Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia. Terapevticheskii arkhiv. 88(7). 62–62. 4 indexed citations

17.

Ковригина, А. М., et al.. (2015). Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma. Terapevticheskii arkhiv. 87(8). 77–77. 2 indexed citations

18.

Ковригина, А. М., et al.. (2014). Front-Line High Dose Therapy with Following Autologous Stem Cell Transplantation (ASCT) for Follicular Lymphoma Patients. Blood. 124(21). 5908–5908. 4 indexed citations

19.

Erkina, Tamara Y., et al.. (2009). Functional interplay between chromatin remodeling complexes RSC, SWI/SNF and ISWI in regulation of yeast heat shock genes. Nucleic Acids Research. 38(5). 1441–1449. 47 indexed citations

20.

Sapojnikova, Nelly, Joseph D Maman, Fiona A. Myers, et al.. (2005). Biochemical observation of the rapid mobility of nuclear HMGB1. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1729(1). 57–63. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact